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Abstract 
A simple, specific, accurate and precise U.V Spectroscopy method was developed and validated for the estimation 
of Seratrodast in pharmaceutical dosage forms. The stock solution was prepared by weighing 100 mg of Standard 
Seratrodast in 100ml volumetric flask containing distilled water. The final stock solution was made to produce 1000µg/ml 
with Methanol. Further dilutions were prepared as per procedure. The linearity was found in the concentration range of 2.5-
25µg/ml. The Correlation coefficient was 0.999. The regression equation was found to be Y = 0.039x + 0.018. The method 
was validated for linearity, accuracy, precision, limit of detection, limit of quantitation, and ruggedness. The limit of 
detection and limit of quantitation for estimation of Seratrodast was found to be 0.169µg/ml and 0.717µgml respectively. 
Recovery of Seratrodast was found to be in the range of 99.1-100.5%. Proposed method was successfully applied for the 
quantitative determination of Seratrodast in pharmaceutical dosage forms. 
Keywords: Seratrodast, U.V-Spectroscopy, Method validation, ICH guidelines. 
 
1. Introduction 
Seratrodast is a thromboxane A2 (TXA2) receptor 
(TP) antagonist used primarily in the treatment of Asthma. 
TXA2 and other bronchoconstrictor prostanoids, 
like PGD2 and PGF2α, are generated in asthma and 
participate in acute and chronic inflammatory processes. 
Seratrodast, being a TP receptor antagonist, inhibits the 
pathophysiological processes in asthma. Chemically it is 
known as 7-Phenly-7(2, 4, 5-trimethyl-3, 6-
dioxocyclohexa-1, 4-dien-1-yl) hepatonic acid. Seratrodast 
is an orally active Quinone derivative and a potent TXA2 
receptor antagonist used in the prophylactic management of 
asthma and treatment of allergic rhinitis.
1-4
The survey of 
literature reveals that good analytical methods are not 
available for drugs like Seratrodast. Even though very few 
methods are available, many of them suffer from one 
disadvantage or the other such as low sensitivity, lack of 
selectivity, and simplicity. In the present work, an attempt 
was made to provide novel, simple, accurate and economic 
UV Specrophotometric method for the effective 
quantitative determination of Seratrodast, in bulk as well as 
in pharmaceutical Dosage forms. The developed methods 
can successfully be applied to estimate the amount of 
Seratrodast in formulations and bulk drugs. The proposed 
method to be validated as per ICH guidelines. 
1.1 Seratrodast: 
Structure:  
 
Figure 1: Chemical Structure of Seratrodast 
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2. Materials and methods:  
2.1 Apparatus and chromatographic parameters:  
Precision balance CA123 Contech, UV-
Spectrophotometer UV-3000 Lab India, UV-
Spectrophotometer UV-1800 Shimadzu and pH Meter3 Star 
Global 
2.2 Preparation of Standard stock solution of 
Seratrodast 
An accurately weighed quantity of 
Seratrodast100mg was transferred to 100ml volumetric 
flask, dissolved in Methanol, the final volume (100ml) was 
made with Methanol to obtain standard solution having 
concentration of 1000μg/mL. 1ml of this solution was 
transferred to 10ml volumetric flask, volume was made 
with Methanol. It gives 100µg/ml. These stock solutions 
were used to prepare further dilutions. 
2.3 Preparation of working standard solutions 
 Six working standard solutions of Seratrodast were 
prepared by pipetting 0.25, 0.5, 1, 1.5, 2, 2.5mL of stock 
solution in 10mL of volumetric flasks and the volume was 
adjusted up to mark by Methanol to make the 
concentrations 2.5, 5, 10, 15, 20, 25μg/ml. 
2.4 Selection of Analytical wavelength 
 For selection of analytical wavelength the standard 
solution was further diluted and then scanned in UV 
spectrophotometer from a range of 200-400nm against 
Methanol as blank and the wavelength corresponding to 
maximum absorbance (λmax) was found at 267ηm. 
2.5 Preparation of sample solution 
Seratrodast is available as tablets of extended 
release containing 80mg of Seratrodast. Seratrodast is 
available in the local market with brand name SERETRA 
80.   
Twenty tablets of Seratrodast were taken and into 
a fine powder of the tablets and the powder equivalent to 
100mg of Seratrodast was weighed accurately and 
transferred into a 100ml standard volumetric flask. The 
contents were dissolved in Methanol and sonicated for 30 
Minutes. This entire solution was filtered through 0.45 
micron Whatmann filter paper (No. 41) and the final 
solution was made with Methanol to get the solution of 
1000μg/ ml. 1ml of this solution was transferred to 10ml 
volumetric flask, volume was made with Methanol. It gives 
100µg/ml.1ml of the solutions were pipetted out separately 
into 10 ml volumetric flask to give 10μg/ml concentration. 
The sample solution absorbance was measured at 267ηmηm 
against blank solution of Methanol. 
2.6 Estimation of drug content in tablet formulation  
Assay procedure 
 Sample solution of10μg/mL of Seratrodast was 
scanned and the absorbance of sample solutions was 
measured. The amount of Seratrodast in tablet dosage form 
was determined and the results obtained were comparable 
with the corresponding label claim to obtain % recoveries. 
 
3. Results and Discussion 
3.1 Assay of commercial formulations 
Table 1: Summary of Assay of commercial formulation 
Conc. 
(µg/ml) 
Formulation 
(SERETRA 
80) 
Label 
claim 
(mg) 
Amount 
found 
(mg) 
% 
Recovery 
10 Tablets 80 80.24 100.30 
 
 
Figure 2: Overlay spectrum of Standard and sample drug 
(20µg/ml) 
3.2 Specificity: 
The analyte was assessed in the presence of the 
components and it was found that there was no interaction 
with the analyte. 
 
Figure 3: Spectrum of Specificity 
3.3 Linearity: 
Various standards in the range 2.5-25μg/ml of 
Seratrodast were observed in to UV system. A graph of 
absorbance (on Y-axis) versus concentration (on X-axis) is 
plotted and the correlation coefficient was calculated as 
shown in Fig No-10 and the Fig No-11 gives the linearity 
overlain spectra for Seratrodast. 
Table 2: Summary of linearity of Seratrodast 
Concentration (µg/ml) Absorbance 267ηm 
0 0 
2.5 0.131 
5 0.220 
10 0.420 
15 0.596 
20 0.808 
25 0.995 
nm.
200.00 250.00 300.00 350.00 400.00
Ab
s.
1.000
0.500
0.000
-0.100
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Figure 4: Linearity graph of Seratrodast 
 
 
Figure 5: Overlay of Linearity graph of Seratrodast 
3.4 Precision: 
Precision of an analytical method is usually 
expressed as standard deviation or relative standard 
deviation. The standard deviation and % relative standard 
deviation are calculated from statistical formula. The 
standard deviation and relative standard deviation for the 
absorbance values were calculated from statistical formula.  
3.4.1 Repeatability: 
Table 3: Summary of system precision 
Concentration (µg/ml) Absorbance 
10 0.421 
10 0.422 
10 0.424 
10 0.423 
10 0.424 
10 0.427 
Mean 0.423 
S.D 0.002 
%R.S.D 0.47 
Table 4: Summary of method precision 
Concentration (µg/ml) %Assay 
10 100.75 
10 100 
10 99.6 
10 100.3 
10 99.8 
10 99.3 
Mean 99.95 
S.D 0.5161 
%R.S.D 0.5162 
 
 
3.4.2 Intermediate Precision: 
Table 5: Summary of Intermediate precision 
Concentration  (µg/ml) Laboratory-1 (%Assay) Laboratory-2 (%Assay) 
 
Analyst-1 Analyst-2 Analyst-1 Analyst-2 
Day-1 Day-2 Day-1 Day-2 Day-1 Day-2 Day-1 Day-2 
10 100.3 99.3 100 100.3 100.5 100 99.8 99.8 
10 100.5 100.3 100.3 100.07 99.8 99.8 99.6 99.6 
10 99.1 99.1 99.8 99.6 99.6 99.8 100.07 99.6 
10 100.3 100 100.7 99.3 100.06 99.3 99.6 99.8 
10 100.07 100.5 100.3 99.8 100.07 100.07 100.3 100.3 
10 100 100.3 100.3 99.6 100.06 100.6 100.3 100.3 
Mean 100.04 99.91 100.23 99.77 100.01 99.92 99.94 99.9 
S.D 0.496 0.581 0.307 0.360 0.303 0.425 0.324 0.322 
%RSD 0.496 0.581 0.306 0.36 0.3 0.42 0.32 0.322 
 
3.5 Reproducibility: 
Table 6: Summary of Reproducibility 
 Laboratory-1 Laboratory-2 
Over All Mean 99.96 99.88 
Mean S.D 0.436 0.343 
Mean %R.S.D 0.435 0.340 
 
Over All Mean 99.96 
Mean S.D 0.389 
Mean %R.S.D 0.388 
 
3.5 Accuracy studies: 
 The accuracy of the method, recovery studies 
were carried out by adding different amounts (50%, 100% 
and 150%) of bulk samples of Seratrodast within the 
linearity range were taken and added to the pre-analyzed 
formulation of concentration 10g/ml. From that 
percentage recovery values were calculated. The results 
were within the range and were found to be highly accurate 
this was shown in table 7. 
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Table 7: Summary of Accuracy studies 
Spiked level 
(%) 
Formulation 
Conc (µg/ml) 
Pure Drug Conc 
(µg/ml) 
Amount 
Found 
% 
Recovery 
% Mean 
recovery 
SD %RSD 
 
50 
10 5 4.97 99.5 
100.1 0.66 0.664 10 5 79.9 100.0 
10 5 80.0 100.9 
 
100 
10 10 79.68 99.6 
100.3 0.62 0.622 10 10 79.68 100.8 
10 10 80.4 100.5 
 
150 
 
10 15 79.4 99.2 
99.5 0.305 0.306 10 15 79.68 99.6 
10 15 79.82 99.8 
 
3.6 Limit of Detection and Limit of Quantification 
 The LOD and LOQ were calculated based on 
the standard deviation of the response and the slope of the 
constructed calibration curve, as described in International 
Conference on Harmonization guidelines Q2 (R1) was 
shown in table 9. 
Table 8: Summary of LOD and LOQ 
Parameter Conc.(µg/ml) 
LOD (Limit of Detection) 0.169 
LOQ (Limit of Quantification) 0.717 
3.7 Robustness: 
 The Robustness of the method was determined 
by making slight changes in the experimental conditions 
such as the temperature and scanning the samples 
maintained at room temperature, cooled to 23°C and heated 
to 27°C (i.e., 25°C±2°C ) as shown in table 9. 
 
 
 
 
Table 9: Summary of Robustness data 
Sample no. Temperature [23˚C (Abs)] Room temperature [25˚C (Abs)] Temperature [27˚C(Abs)] 
1 0.434 0.423 0.454 
2 0.431 0.42 0.456 
3 0.43 0.427 0.455 
4 0.43 0.427 0.456 
5 0.43 0.424 0.457 
6 0.431 0.427 0.458 
Mean 0.431 0.424 0.456 
S.D 0.0015 0.0028 0.0014 
%R.S.D 0.232 0.204 0.219 
 
 
3.8 Forced Degradation Study 
Drug samples were subjected to alkaline 
hydrolysis using 0.1N NaOH, Acid hydrolysis using 0.1N 
HCl, peroxide oxidation using 3% H2O2, thermal and  
photolysis, treated samples were scanned and their 
respective spectra were recorded and the Changes in 
absorbance value were recorded and the results were shown 
in table 10 and the absorption spectra were shown in figures 
6-10. 
 
 
 
 
 
 
 
Figure 6: Spectrum of Seratrodastin 0.1N HCl  
(Acidic condition) 
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Figure 7: Spectrum of Seratrodast in 0.1N NaOH  
(Basic condition) 
 
 
Fig.8: Spectrum of Seratrodast in 3% H2O2  
(Oxidation condition) 
 
Fig.9: Spectrum of Seratrodast in   Photolysis condition  
 
 
 
Fig.10: Spectrum of Seratrodast in thermal Condition 
 
 
Table 10: Summary of Forced Degradation analysis 
Degradation 
Parameters 
Absorbance 
Concentration 
(µg/ml) 
%Drug Recovered % Drug Decomposed Degradation time 
Normal condition 
(Water) 
0.421 10 100 0 90mins 
Acidic degradation 
(0.1N HCl) 
0.388 9.21 92.1 7.9 90mins 
Basic degradation 
(0.1N NaOH) 
0.422 10.02 100.2 0 90mins 
Peroxide degradation 
(3% H2O2) 
1.009 23.96 0 100 90mins 
Photolysis  
Condition 
0.282 6.69 66.98 33.02 90mins 
Thermal 
condition 
0.423 
 
10.04 
100.4 0 90mins 
 
4. Conclusion 
A simple method was developed for the 
determination of Seratrodast in pure and its pharmaceutical 
formulations. Seratrodast exhibited maximum absorption at 
267ηm in distilled water and obeyed linearity in the 
concentration range of 2.5-25μg/ml. The proposed method 
was statistically validated. This study presents a simple 
stability-indicating UV spectroscopic method for estimation 
of Seratrodast in the presence of degradation products. By 
the forced degradation studies, it was found that the drug 
Seratrodast is degraded in the thermal condition as per the 
studies performed. So it was concluded that the drug should 
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be stored in cool and dark place, away from air. The 
proposed study describes a new UV-Spectrophotometric 
method for the Estimation of Seratrodast in bulk and 
combined dosage form. A UV-Spectrophotometric method 
was developed using distilled water as solvent. The 
developed methods were validated in accordance with ICH 
guidelines and all of the results were within the limits. 
The UV method for the Estimation of Seratrodast 
in tablet dosage form was also found to be simple, rapid, 
precise, accurate and sensitive. A good agreement was 
observed in UV method. The validated UV method can be 
used for the routine analysis of quality control samples. 
Since the developed methods have been applied only to a 
single brand (SERETRA 80), the same methods are 
applicable to different brands. 
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